Printer Friendly

Nippon Boehringer Ingelheim, Pfizer Japan Jointly Survey Japanese People Older Than 40 on COPD.

Tokyo, Japan, Oct 26, 2005 - (JCNN) - Nippon Boehringer Ingelheim and Pfizer Japan jointly announced on October 25 the results of their awareness survey on chronic obstructive pulmonary disease (COPD), in which 7,609 people aged 40 or older (4,364 men and 3,245 women) answered via the Internet from September 16 to 20.

Of the respondents, 23.6% said that they recognize the disease, COPD, and 24.1% are suspected of having COPD. Of those with suspected COPD, 28.7% know of the disease. When asked about the understanding of COPD in those who know of the disease, 56.8% understand that COPD causes breath shortness, chronic cough and sputum.

Of those with suspected COPD, only 5.1% have consulted with a doctor. When asked about the reason why they decided to go see a doctor, 44.4% answered that they noticed symptoms to a certain extent while 29.6% said that they became anxious after they read a newspaper article or watched a TV program on COPD.

In turn, of those who are suspected COPD and have never consulted a doctor, 65.4% answered that they are not affected with the disease.

The survey defines suspected COPD patients as those who have three or more of the following symptoms: 1) cough several times a day; 2) produce yellowish, viscous sputum several times a day; 3) easily become short of breath compared to others in the same age group; 4) aged 40 or older; and 5) currently smoke or have a smoking history.

Detailed survey results in English are available at Nippon Boehringer Ingelheim's Official Web Site <http://www.boehringer-ingelheim.co.jp/news/p-release_e/05_1025_a-e.html>.

Source: JCN http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:9JAPA
Date:Oct 28, 2005
Words:296
Previous Article:Syngenta Japan Now Markets New Non-selective Herbicide TOUCHDOWN iQ.
Next Article:Ono Pharmaceutical Announces Termination of Patient Enrollment for Phase III Clinical Trial of Investigational AIDS Drug.
Topics:


Related Articles
BOEHRINGER STANDARDIZES ON SIEBEL EBUSINESS APPLICATIONS.
Boehringer Ingleheim just wants to have a little `fun' with root for loot. (Thinking Outside The Box).
GRAFFINITY SIGNS COLLABORATION AGREEMENT WITH ELI LILLY.
MORPHOSYS/PFIZER TO DEVLOP THERAPEUTIC ANTIBODIES.
Pfizer Japan Surveys Japanese Men Age Over 30 on Health and Sex.
Nippon Boehringer Ingelhemi to Solely Market Alesion Anti-allergic Agent.
Nippon Boehringer Ingelheim Begins Promoting Central Nervous System Drugs Lendormin and Bi-Sifrol Via MR-Kun Information Service.
Boehringer Ingelheim Vetmedica Japan Begins Distributing Animal Health Products.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters